Profil
Chris Riley currently works at Andelyn Biosciences, Inc., as Director from 2022.
Postes actifs de Chris Riley
| Sociétés | Poste | Début |
|---|---|---|
Andelyn Biosciences
 Andelyn Biosciences BiotechnologyHealth Technology Andelyn Biosciences is a full-service cell and gene therapy company that specializes in the development, characterization, and production of viral vectors for gene therapy. The private company is based in Columbus, OH. The company operates out of three facilities in Ohio and offers support to its clients in developing curative cell and gene therapies from concept through plasmid development and manufacturing, process development, and cgmp clinical and commercial manufacturing. Andelyn's advanced digital model, quality system, full regulatory support, and supply chain vertical integration help accelerate the development and manufacturing of its clients' innovative cell and gene therapies. The company has more than 20 years of experience and has produced cgmp material for over 450 clinical batches and 75 clinical trials. Andelyn's versatile capabilities include cgmp manufacturing capacity for both adherent and suspension processes up to a 2,000-liter capacity. The CEO of the company is Wade Macedone. | Directeur/Membre du Conseil | 01/01/2022 |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 1 |
|---|---|
Andelyn Biosciences
Andelyn Biosciences BiotechnologyHealth Technology Andelyn Biosciences is a full-service cell and gene therapy company that specializes in the development, characterization, and production of viral vectors for gene therapy. The private company is based in Columbus, OH. The company operates out of three facilities in Ohio and offers support to its clients in developing curative cell and gene therapies from concept through plasmid development and manufacturing, process development, and cgmp clinical and commercial manufacturing. Andelyn's advanced digital model, quality system, full regulatory support, and supply chain vertical integration help accelerate the development and manufacturing of its clients' innovative cell and gene therapies. The company has more than 20 years of experience and has produced cgmp material for over 450 clinical batches and 75 clinical trials. Andelyn's versatile capabilities include cgmp manufacturing capacity for both adherent and suspension processes up to a 2,000-liter capacity. The CEO of the company is Wade Macedone. | Health Technology |
